INTERFERON α-2B BY CONTINUOUS SUBCUTANEOUS INFUSION IN COMBINATION WITH RIBAVIRIN FOR TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS: 12 WEEK INTERIM ANALYSIS

被引：0
|
作者：
Muir, Andrew J. [1 ]
Bacon, Bruce R. [2 ]
Gitlin, Norman [4 ]
Kugelmas, Marcelo [3 ]
Tillman, Hans L. [1 ]
Grovender, Eric A. [5 ]
Van Antwerp, Bill [5 ]
Mische, Sarah [5 ]
Kwo, Paul Y. [6 ]
机构：
[1] Duke Clin Res Inst, Durham, NC USA
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] S Denver Gastroenterol, Englewood, CO USA
[4] Atlanta Gastroenterol Associates, Atlanta, GA USA
[5] Medtronic, Ventures & New Therapies, Minneapolis, MN USA
[6] Indiana Univ Sch Med, Indianapolis, IN USA
来源：
HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1439A / 1439A
页数：1
相关论文
共 50 条
  • [21] Interferon alfa 2B alone or in combination with ribavirin in naive chronic HCV patients: A US multicenter trial.
    McHutchison, J
    Gordon, S
    Schiff, E
    Shiffman, M
    Lee, W
    Rustgi, V
    Albrecht, J
    HEPATOLOGY, 1998, 28 (04) : 387A - 387A
  • [22] PROSPECTIVE WEEK 12 INTERIM PK/PD ANALYSIS RESULTS FROM THE COPE-HCV STUDY: HIGH-DOSE NON-PEGYLATED INTERFERON ALPHA-2B DELIVERED BY CONTINUOUS SUBCUTANEOUS INFUSION TO THERAPY-NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1
    Grovender, Eric A.
    Lande, Jeff
    Hamlen, Cushing
    Mische, Sarah
    Juth, Suzanne
    Van Antwerp, Bill
    HEPATOLOGY, 2011, 54 : 1436A - 1437A
  • [23] Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naive Patients: Final Results of Phase 3 ADVANCE Study
    Ferenci, Peter
    Jacobson, Ira M.
    Adda, Nathalie
    Bengtsson, Leif
    George, Shelley
    Kauffman, Robert
    Zeuzem, Stefan
    SWISS MEDICAL WEEKLY, 2011, 141 : 3S - 3S
  • [24] TELAPREVIR IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN GENOTYPE 1 HCV TREATMENT-NAIVE PATIENTS: FINAL RESULTS OF PHASE 3 ADVANCE STUDY
    Jacobson, Ira M.
    McHutchison, John G.
    Dusheiko, Geoffrey M.
    Di Bisceglie, Adrian M.
    Reddy, Rajender
    Bzowej, Natalie H.
    Marcellin, Patrick
    Muir, Andrew J.
    Bengtsson, Leif
    Dunne, Ann Marie
    Adda, Nathalie
    George, Shelley
    Kauffman, Robert S.
    Zeuzem, Stefan
    HEPATOLOGY, 2010, 52 (04) : 427A - 427A
  • [25] TELAPREVIR IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN GENOTYPE 1 HCV TREATMENT-NAIVE PATIENTS: FINAL RESULTS OF PHASE 3 ADVANCE STUDY
    Dusheiko, G. M.
    Bengtsson, L.
    Adda, N.
    Kauffman, R.
    Jacobson, I. M.
    GUT, 2011, 60 : A32 - A33
  • [26] TMC435 IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1 PATIENTS: FINAL ANALYSIS OF THE PILLAR PHASE IIB STUDY
    Fried, Michael
    Buti, Maria
    Dore, Gregory J.
    Flisiak, Robert
    Ferenci, Peter
    Jacobson, Ira M.
    Marcellin, Patrick
    Manns, Michael P.
    Nikitin, Igor
    Poordad, F. Fred
    Sherman, Morris
    Zeuzem, Stefan
    Lenz, Oliver
    Peeters, Monika
    Sekar, Vanitha
    De Smedt, Goedele
    HEPATOLOGY, 2011, 54 : 1429A - 1429A
  • [27] TMC435 IN COMBINATION WITH PEGINTERFERON ALPHA-2A/RIBAVIRIN IN TREATMENT-NAiVE PATIENTS INFECTED WITH HCV GENOTYPE 1: VIROLOGY ANALYSIS OF THE PILLAR STUDY
    Lenz, Oliver
    Fevery, Bart
    Vijgen, Leen
    Verbeeck, Jannick
    Peeters, Monika
    Beumont, Maria
    Fried, Michael W.
    Picchio, Gaston
    HEPATOLOGY, 2011, 54 : 985A - 985A
  • [28] FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES
    Asselah, T.
    Jensen, D. M.
    Foster, G. R.
    Sulkowski, M. S.
    Ouzan, D.
    Morano, L.
    Buynak, R.
    Agarwal, K.
    Hassanein, T.
    Forton, D.
    Negro, F.
    Genne, D.
    Kaita, K.
    Maieron, A.
    Preotescu, L.
    Sarrazin, C.
    Zehnter, E.
    Romero-Gomez, M.
    Stern, J. O.
    Quinson, A. -M.
    Drulak, M.
    Garcia, M.
    Voss, F.
    Boecher, W.
    Ferenci, P.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S310 - S311
  • [29] Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naive Patients: Pooled Analysis of Phase III Studies
    Asselah, Tarik
    Jensen, Donald M.
    Foster, Graham
    Sulkowski, Mark
    Ouzan, Denis
    Morano, Luis
    Buynak, Robert
    Agarwal, Kosh
    Hassanein, Tarek
    Forton, Daniel
    Negro, Francesco
    Genne, Daniel
    Kaita, Kelly
    Maieron, Andreas
    Preotescu, Liliana
    Sarrazin, Christoph
    Zehnter, Elmar
    Romero-Gomez, Manuel
    Stern, Jerry O.
    Quinson, Anne-Marie
    Drulak, Murray
    Garcia, Miguel
    Voss, Florian
    Boecher, Wulf
    Ferenci, Peter
    GASTROENTEROLOGY, 2014, 146 (05) : S977 - S977
  • [30] BASELINE FACTORS ASSOCIATED WITH INCREASED SVR RATES IN 123 TREATMENT-NAIVE CHRONIC HCV GENOTYPE 1 PATIENTS TREATED WITH A SHORTENED 12-WEEK SIMEPREVIR PLUS PEGYLATED INTERFERON AND RIBAVIRIN REGIMEN: A MULTIVARIATE ANALYSIS
    Asselah, T.
    Moreno, C.
    Sarrazin, C.
    Gschwantler, M.
    Foster, G. R.
    Craxi, A.
    Buggisch, P.
    Ryan, R.
    Lenz, O.
    Van Dooren, G.
    Lonjon-Domanec, I.
    Schlag, M.
    Buti, M.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S629 - S630
12345